Missed Doses of Oral vs Weekly Semaglutide

A research letter published in Diabetes, Obesity and Metabolism on 23 June 2026 compared what happens to drug concentrations when someone misses doses of five GLP-1 based treatments, including once-daily oral semaglutide and the once-weekly semaglutide injection^[1]. The modelling's short version is that a daily tablet with a one-week half-life behaves very differently from a daily drug that clears in half a day. What to do about a dose you have already missed is a question for the prescriber or pharmacist who dispensed it, and the answer is different for each product. What follows is what the labels state and what the modelling reported.

What the labels state about a missed dose

The US prescribing information covering semaglutide tablets, sold as Rybelsus at 3 mg, 7 mg and 14 mg and as Ozempic tablets at 1.5 mg, 4 mg and 9 mg, says: "If a dose is missed, skip the missed dose and take the next dose the following day."^[3] Wegovy's label carries the same sentence for its 25 mg once-daily tablet^[4]. Instructions for the once-weekly injection read differently. If one injection dose is missed and the next scheduled dose is more than 2 days away, the Wegovy label says to administer it as soon as possible, while if the next scheduled dose is less than 2 days away it says not to administer the missed dose^[4]. For longer gaps the same label adds that if 2 or more consecutive injection doses are missed, reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions^[4].

It is the same molecule by two delivery routes, with two different sets of instructions, which is why a pharmacist beats a search engine here. In the EU the oral version has been authorised since 3 April 2020 as a once-daily tablet for adults with insufficiently controlled type 2 diabetes, with Novo Nordisk A/S as the marketing authorisation holder^[5]. Our notes on semaglutide's regulatory status track that authorisation country by country.

Why the tablet and the weekly injection drift apart

Semaglutide's elimination half-life is approximately one week, according to the tablet label^[3]. Give a drug every day when it takes a week to clear half of it, and concentrations stack up into a plateau. Dropping one day barely shifts that plateau. The letter's simulations put figures on it. Working from published population pharmacokinetic models of maximum plasma concentrations, the authors report that for oral semaglutide 25 mg a decline in exposure of 50% or more appeared only after 7 days of missed doses. For once-daily oral orforglipron 36 mg (half-life 1 to 2 days), once-daily injected liraglutide 3 mg (half-life 0.5 days) and once-weekly injected tirzepatide 15 mg (half-life 5 days), the same 50% drop showed up after a single missed dose^[1].

The second half of the letter is about restarting. Coming back after a gap can push concentrations up sharply, and the authors report relative exposure increases of roughly 400% to 700% on reinitiation for liraglutide and orforglipron after 3 days of missed doses^[1]. They note that liraglutide and orforglipron users are instructed to reinitiate at lower doses after 3 and 7 missed doses respectively, while for oral semaglutide there is no recommendation to reinitiate treatment at a lower dose^[1].

Read the comparison with the sponsor in view

Four of the five authors, Rune Viig Overgaard, Henrik Agersø, Christian Hollensen and Naveen Rathor, are employees of and shareholders in Novo Nordisk A/S^[2]. Novo Nordisk makes oral semaglutide. The fifth author, Eric M. Bomberg at the University of Minnesota Medical School, has been a site principal investigator and co-investigator for Novo Nordisk phase 3 paediatric trials, and his research is supported by a National Institute of Diabetes and Digestive and Kidney Diseases career development award (K23DK125668)^[2]. The letter concludes that semaglutide and subcutaneous tirzepatide "may be less affected by deviations from the prescribed dosing regimen" than other GLP-1 based therapies^[1], which is a conclusion that flatters the employer of most of its authors. That does not make the pharmacokinetics wrong. It does mean the framing deserves an independent check before anyone repeats it as neutral.

This is a letter, not a trial

PubMed classifies the paper as a Letter, five journal pages^[2]. No patient took anything for it. The analysis is a simulation run on already-published pharmacokinetic models, and it reports drug concentrations, not blood glucose, not weight change, not adverse events. The authors flag one limit themselves: the therapies they compared "are inherently different"^[1]. A single missed dose of a once-weekly injection means seven days without the drug, while a single missed dose of a daily tablet means one, so comparing products on their own dosing schedules is not comparing equal gaps.

What we do not yet know

Whether these concentration differences change blood glucose control, weight outcomes or side effects in real patients is unanswered, because the letter measured none of those. A trial that deliberately assigned people to miss doses would be hard to justify, so the question may stay in the modelling domain for a while. We also do not know how well the models hold in the groups most likely to interrupt treatment. The letter acknowledges that missing doses "may result from both personal and healthcare/insurance-related causes"^[1] and leaves it there. Cost, supply shortages and side effects all interrupt treatment in practice, and none of those were modelled.

What this means for readers

Your product's label has a specific answer, and another product's answer does not transfer to it. Our semaglutide reference page and tirzepatide page set out the approved formulations and what each label covers. For a dose you have actually missed, ask the prescriber or pharmacist who dispensed it.

This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.